Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis

English version České info

Background:
Diabetes imposes a substantial burden globally in terms of premature mortality, morbidity, and health care costs. Estimates of economic outcomes associated with diabetes are essential inputs to policy analyses aimed at prevention and treatment of diabetes. Our objective was to estimate and compare event rates, hospital utilization, and costs associated with major diabetes-related complications in high-, middle-, and low-income countries.

Methods and Findings:
Incidence and history of diabetes-related complications, hospital admissions, and length of stay were recorded in 11,140 patients with type 2 diabetes participating in the Action in Diabetes and Vascular Disease (ADVANCE) study (mean age at entry 66 y). The probability of hospital utilization and number of days in hospital for major events associated with coronary disease, cerebrovascular disease, congestive heart failure, peripheral vascular disease, and nephropathy were estimated for three regions (Asia, Eastern Europe, and Established Market Economies) using multiple regression analysis. The resulting estimates of days spent in hospital were multiplied by regional estimates of the costs per hospital bed-day from the World Health Organization to compute annual acute and long-term costs associated with the different types of complications. To assist, comparability, costs are reported in international dollars (Int$), which represent a hypothetical currency that allows for the same quantities of goods or services to be purchased regardless of country, standardized on purchasing power in the United States. A cost calculator accompanying this paper enables the estimation of costs for individual countries and translation of these costs into local currency units. The probability of attending a hospital following an event was highest for heart failure (93%–96% across regions) and lowest for nephropathy (15%–26%). The average numbers of days in hospital given at least one admission were greatest for stroke (17–32 d across region) and heart failure (16–31 d) and lowest for nephropathy (12–23 d). Considering regional differences, probabilities of hospitalization were lowest in Asia and highest in Established Market Economies; on the other hand, lengths of stay were highest in Asia and lowest in Established Market Economies. Overall estimated annual hospital costs for patients with none of the specified events or event histories ranged from Int$76 in Asia to Int$296 in Established Market Economies. All complications included in this analysis led to significant increases in hospital costs; coronary events, cerebrovascular events, and heart failure were the most costly, at more than Int$1,800, Int$3,000, and Int$4,000 in Asia, Eastern Europe, and Established Market Economies, respectively.

Conclusions:
Major complications of diabetes significantly increase hospital use and costs across various settings and are likely to impose a high economic burden on health care systems.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis. PLoS Med 7(2): e32767. doi:10.1371/journal.pmed.1000236
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000236

Souhrn

Zdroje

1. WildS

RoglicG

GreenA

SicreeR

KingH

2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 1047 1053

2. GuK

CowieCC

HarrisMI

1998 Mortality in adults with and without diabetes in a national cohort of the U. S. population, 1971–1993. Diabetes Care 21 1138 1145

3. RoperNA

BilousRW

KellyWF

UnwinNC

ConnollyVM

2001 Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 322 1389 1393

4. NarayanKM

BoyleJP

ThompsonTJ

SorensenSW

WilliamsonDF

2003 Lifetime risk for diabetes mellitus in the United States. JAMA 290 1884 1890

5. SelbyJV

RayGT

ZhangD

ColbyCJ

1997 Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 20 1396 1402

6. RamachandranA

RamachandranS

SnehalathaC

AugustineC

MurugesanN

2007 Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India. Diabetes Care 30 252 256

7. RubinR

AltmanWM

MendelsonDN

1994 Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 78 809A 809F

8. NarayanKM

ZhangP

KanayaAM

WilliamsDE

EngelgauMM

2006 Diabetes: The pandemic and potential solutions. Disease control priorities in developing countries. 2nd edition. New York Oxford University Press 591 604

9. International Diabetes Federation 2006 Diabetes atlas. 3rd Edition. Brussels International Diabetes Federation

10. PatelA

MacMahonS

ChalmersJ

NealB

BillotL

2008 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 2560 2572

11. AdamT

EvansDB

MurrayCJL

2003 Econometric estimation of country–specific hospital costs. Cost Eff Resour Alloc 1 3

12. ADVANCE Management Committee 2001 Study rationale and design of ADVANCE: action in diabetes and vascular disease—preterax and diamicron MR controlled evaluation. Diabetologia 44 1118 1120

13. WooldridgeJM

2001 Econometric analysis of cross section and panel data. Boston: MIT Press.

14. DigglePJ

HeagertyPJ

LiangK-Y

ZegerSL

2002 Analysis of longitudinal data. 2nd Edition. Oxford Oxford University Press

15. Rabe-HeskethS

SkrondalA

2005 Multilevel and longitudinal modeling using stata. College Station (Pennsylvania) Stata Press

16. Liang KY ZegerSL

1986 Longitudinal data analysis using generalized linear models Biometrika 73 13 22

17. JonesAM

2000 Health econometrics.

CulyerAJ

NewhouseJP

Handbook of health economics. Edition 1, volume 1, chapter 6 Amsterdam Elsevier 265 344

18. World Health Organization 2003 Making choices in health: WHO guide to cost-effectiveness analysis. Geneva World Health Organization

19. World Health Organization 2009 World health statistics 2009. Geneva World Health Organization

20. RubinRJ

AltmanWM

MendelsonDN

1994 Health expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 78 809A 809F

21. HenrikssonF

AgardhC-D

BerneC

BolinderJ

LönnqvistF

2000 Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 248 387 396

22. JönssonB

2002 Revealing the cost of Type II diabetes in Europe. Diabetologia 45 S5 S12

23. HoganP

DallT

NikolovP

American Diabetes Association 2003 Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26 917 932

24. American Diabetes Association 2008 Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31 596 615

25. RayappaPH

RajuKNM

KapurA

BjorkS

SylvestC

KumarDMD

1999 The impact of socio-economic factors on diabetes care. Int J Diab Dev Countries 19 7 19

26. WangW

FuCW

PanCY

ChenW

ZhanS

2009 How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China? Value Health 12 923 929

27. ClarkePM

GrayAM

BriggsA

StevensRJ

MatthewsDR

HolmanRR

2005 Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 48 868 877

28. HermanWH

HoergerTJ

BrandleM

HicksK

SorensenS

2005 Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142 323 332

29. XieX

VondelingH

2008 Metformin cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health 11 S23 S32

30. RamachandranA

SnehalathaC

YamunaA

MaryS

ZhangP

2007 Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 30 2548 2552

31. ClarkeP

GrayA

LegoodR

BriggsA

HolmanR

2003 The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 20 442 450